Neuropathic Pain, Spinal Cord Injuries
Conditions
Brief summary
In summary, this small-scale study is designed to demonstrate that the NFX88 is safe and well tolerated, as well as preliminary evidence of improvement in the score of VAS, PD-Q, and PGIC scales.
Detailed description
This is a Phase IIa (proof of concept), randomized, double-blind, placebo controlled, parallel group, multicentric, clinical trial to evaluate the safety, tolerability and efficacy of daily oral treatment with NFX88 in SCI patients who are not receiving opiates or cannabinoids and present neuropathic pain with an average pain score ≥ 4 measured with a VAS scale during the last week at screening
Interventions
DRUGNFX88 - 1
3 times a day
DRUGNFX88 - 2
3 times a day
DRUGNFX88 - 3
3 times a day
DRUGPLACEBO - 4
3 times a day
Sponsors
Neurofix S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Able and willing to provide written informed consent. 2. Male or Female 18 to 65 years of age. 3. Traumatic complete or incomplete spinal cord injury with C4-T12 level and more than three months since injury. 4. Diagnosed of neuropathic pain with an average pain score ≥ 4 measured using the VAS scale during the last week. 5\. Stable treatment, for at least 1 month, with pregabalin 150-300 mg/day, that should be maintained at the same dose for 90 days until the end of the study treatment. 6\. Normotensive patients defined as patients with blood pressure values between 90-160 for systolic pressure and 50-100 for diastolic pressure. 7\. Patients who have been treated with stable doses of neuroactive drugs (antidepressants, anticonvulsants, antispastic and similar medicines) at least during the last month, can also be recruited. 8\. Availability for the entire study period, absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; willingness to adhere to the protocol requirements, ability to cooperate adequately, to understand and follow the instructions of the physician or designee. 9\. Women who are not postmenopausal (at least 12 months) or surgically sterile must have a negative pregnancy test at screening and at the end of study and either abstain from sexual intercourse or use a highly effective method of birth control for the duration of the study and after 12 weeks after the last dose of study drug. 10\. For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm for the duration of the study and after 12 weeks from the last dose of study drug.
Exclusion criteria
1. Patients treated with opiates (major and minor) and cannabinoids (synthetic, natural or analogous). 2. Patients with blood pressure higher than those accepted in the inclusion criteria. 3. History of alcohol, drug abuse within 6 months prior to screening. 4. Psychiatric patients or those with moderate or severe cognitive impairment. 5. Patient who is pregnant or lactating. 6. Patient who shows evidence of significant liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. 7. Patient who has clinically significant diseases and/or infections captured in the medical history or evidence of clinically significant findings on physical examination and/or clinically significant ordinary laboratory evaluations (haematology, biochemistry, and urinalysis) or ECG. 8. Patient who is currently participating in another clinical trial of an investigational drug or medical device within 90 days prior to screening. 9. Inability to comply with study protocol. 10. Patient unable to swallow 12 1-gram tablets. 11. History of cancer except local basal or squamous cell carcinoma of the skin that has been excised.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of specific laboratory abnormalities | 90 days | Safety and tolerability of NFX88 administered for 90 days will be evaluated by assessing specific abnormalities of laboratory values |
| Incidence of serious adverse events | 90 days | Safety and tolerability of NFX88 administered for 90 days will be evaluated by assessing the number of AE |
| Incidence of severity adverse events | 90 days | Safety and tolerability of NFX88 administered for 90 days will be evaluated by assessing the severity and type of AE |
| No changes in MAS and AIS scales. | 90 days | Safety and tolerability of NFX88 administered for 90 days will be evaluated by assessing that there are not relevant changes in the MAS (e.g. to monitor spasticity worsening) and ASIA (e.g. to monitor neurological worsening) scores. |
| Incidence of relevant changes in vital signs | 90 days | Safety and tolerability of NFX88 administered for 90 days will be evaluated by assessing that there are not relevant changes in vital signs that may affect the safety of the patient |
| Incidence of relevant changes in 12-lead ECGs | 90 days | Safety and tolerability of NFX88 administered for 90 days will be evaluated by assessing the ECGs to prove that there are not relevant changes in this test through the trial |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in neuropathic pain scales VAS, PD-Q, and PGIC | 90 days | Reduction from V1 to EoT in pain intensity in the VAS scale, reduction from SV to EoT in the likelihood of neuropathic pain in PD-Q scale and global improvement at EoT in patient's condition according to the PGIC scale. |
Countries
Spain
Outcome results
None listed